Skip to main content
Journal of the Endocrine Society logoLink to Journal of the Endocrine Society
. 2021 Jun 5;5(9):bvab057. doi: 10.1210/jendso/bvab057

Calcium-Sensing Receptors Control CYP27B1-Luciferase Expression: Transcriptional and Posttranscriptional Mechanisms

Alice Huang 1, Lenah Binmahfouz 2,3, Dale P Hancock 1, Paul H Anderson 4, Donald T Ward 2, Arthur D Conigrave 1,
PMCID: PMC8317635  PMID: 34337274

Abstract

25-hydroxyvitamin D 1α-hydroxylase (encoded by CYP27B1), which catalyzes the synthesis of 1,25-dihydroxyvitamin D3, is subject to negative or positive modulation by extracellular Ca2+ (Ca2+o) depending on the tissue. However, the Ca2+ sensors and underlying mechanisms are unidentified. We tested whether calcium-sensing receptors (CaSRs) mediate Ca2+o-dependent control of 1α-hydroxylase using HEK-293 cells stably expressing the CaSR (HEK-CaSR cells). In HEK-CaSR cells, but not control HEK-293 cells, cotransfected with reporter genes for CYP27B1-Photinus pyralis (firefly) luciferase and control Renilla luciferase, an increase in Ca2+o from 0.5mM to 3.0mM induced a 2- to 3-fold increase in firefly luciferase activity as well as mRNA and protein levels. Surprisingly, firefly luciferase was specifically suppressed at Ca2+o ≥ 5.0mM, demonstrating biphasic Ca2+o control. Both phases were mediated by CaSRs as revealed by positive and negative modulators. However, Ca2+o induced simple monotonic increases in firefly luciferase and endogenous CYP27B1 mRNA levels, indicating that the inhibitory effect of high Ca2+o was posttranscriptional. Studies with inhibitors and the CaSR C-terminal mutant T888A identified roles for protein kinase C (PKC), phosphorylation of T888, and extracellular regulated protein kinase (ERK)1/2 in high Ca2+o-dependent suppression of firefly luciferase. Blockade of both PKC and ERK1/2 abolished Ca2+o-stimulated firefly luciferase, demonstrating that either PKC or ERK1/2 is sufficient to stimulate the CYP27B1 promoter. A key CCAAT box (−74 bp to −68 bp), which is regulated downstream of PKC and ERK1/2, was required for both basal transcription and Ca2+o-mediated transcriptional upregulation. The CaSR mediates Ca2+o-dependent transcriptional upregulation of 1α-hydroxylase and an additional CaSR-mediated mechanism is identified by which Ca2+o can promote luciferase and possibly 1α-hydroxylase breakdown.

Keywords: calcium-sensing receptor, CYP27B1, 1αOHase, PKC, Thr-888 phosphorylation, ERK1/2, transcription, protein synthesis, protein breakdown


The mitochondrial membrane enzyme 25-hydroxyvitamin D 1α-hydroxylase (1αOHase), which is encoded by the CYP27B1 gene, catalyzes the synthesis of 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3; calcitriol). The hormonal form of 1,25(OH)2D3, which is generated in the renal proximal tubule [1], acts systemically to promote intestinal calcium and inorganic phosphate absorption and thereby plays a key role in whole-body mineral metabolism (reviews: [2-5]). Consistent with this role, mutations of CYP27B1 that impair the structure and/or function of 1αOHase cause vitamin D-dependent rickets type-1 (VDDR-I), typified by low plasma ionized calcium and phosphate concentrations, and mineralization defects [6, 7] and many but not all of the effects of CYP27B1 deficiency are restored by calcium- and phosphate-rich rescue diets (review: [8]).

Thus, 1,25(OH)2D3 generated locally in extrarenal tissues via 1αOHase encoded by the same CYP27B1 gene, acts via vitamin D receptor–dependent and vitamin D receptor–independent paracrine, autocrine, and even intracrine mechanisms to modulate cellular responses. While the full significance of these effects and the nature of their local control remains unclear, they include inhibition of parathyroid hormone transcription [9-11], negative control of parathyroid hyperplasia [12], phenotypic modulation of growth plate chondrocytes [13], basal levels of osteoblastic bone formation [12], and immunomodulatory and bactericidal actions in cells of the monocyte/macrophage lineage (review: [14]).

1αOHase activity is modulated differentially by hormones, cytokines, and nutrients according to the cell type in which it is expressed. In renal proximal tubule epithelial cells, key modulators include the hormones parathyroid hormone (PTH) and calcitonin, which are stimulatory [15], and 1,25(OH)2D3 [15] and fibroblast growth factor 23 (FGF23) [16-19], which are inhibitory. These hormones act, at least in part, on the promoter region of the CYP27B1 gene via receptor-dependent signaling mechanisms. Thus, PTH [20-23]) and calcitonin [24] increase and 1,25(OH)2D3 [21, 25] and FGF23 [19] suppress CYP27B1 mRNA levels.

Two key nutrients that have been identified previously as modulators of CYP27B1 and its encoded enzyme 1αOHase include calcium [26-28] and inorganic phosphate [29]. These effects operate in part systemically via Ca2+o- (review: [30]) and inorganic phosphate- [31] dependent control of PTH secretion and by phosphate-dependent control of FGF23 secretion from osteocytes (review: [4]). They also operate locally, that is, directly on cells of the proximal tubule, parathyroid, and osteoblast lineage. Thus Ca2+o, independent of its effects on PTH [27], directly suppresses 1αOHase activity in the proximal tubule [28] but stimulates it in other sites, including parathyroid cells [32] and osteoblasts [33]. Whether the inhibitory effect of Ca2+o on 1αOHase activity in the proximal tubule and stimulatory effect of Ca2+o on 1αOHase activity in extrarenal tissues are mediated by a plasma membrane receptor and via CYP27B1 transcription or some other mechanism have not been elucidated.

The extracellular calcium-sensing receptor (CaSR) is a widely expressed Ca2+-sensor responsible for mediating diverse Ca2+o-dependent effects. In the parathyroid, the CaSR mediates Ca2+o-dependent inhibition of PTH synthesis and secretion (review: [30]). In the renal proximal tubule, where it is expressed but at relatively low levels [34] it mediates Ca2+o-induced disinhibition of the phosphaturic action of PTH [35] and may thus also impair PTH-induced upregulation of 1αOHase. In osteoblasts and chondrocytes, the CaSR promotes cellular maturation leading to enhanced matrix synthesis and mineralization ([36]; review: [37]), at least in part via a newly described signaling pathway dependent on phospho-Akt [38, 39]. In addition, tissue-specific knockouts of the floxed CaSR in chondrocytes (targeted via the type-II collagen promoter) and in osteoblasts (targeted via the type-I collagen promoter) resulted in major developmental abnormalities and growth retardation in mice [40]. These considerations led us to hypothesize that one or more actions of Ca2+o on 1,25(OH)2D3 synthesis via 1αOHase, including suppressed synthesis in the renal proximal tubule and/or stimulated synthesis in extrarenal tissues such as the parathyroid and skeletal osteoblasts, might be mediated by the CaSR.

Consistent with our hypothesis, the CaSR is expressed in proximal tubule epithelial cells ([34]; review [41]), parathyroid cells [42], growth plate chondrocytes, and osteoblasts (review: [43]). However, none of the commonly used cell models from these tissues appeared suitable for a test of our hypothesis since they are difficult to maintain in primary culture and to transfect, and they exhibit downregulation of the CaSR ([44]) and other key receptors (eg, PTH1R in proximal tubule cells; [45]). We therefore focused on a cell type that expresses the CaSR stably and robustly, that can be readily transfected with constructs suitable for evaluating CaSR-mediated control of CYP27B1 expression, and for which there is an appropriate CaSR-null control.

For these reasons, in the present study we investigated whether the CaSR mediates Ca2+o-dependent control of CYP27B1 promoter–dependent luciferase expression using a well-defined model cell type, HEK-293 cells that stably express the CaSR (HEK-CaSR cells). HEK-293 cells were previously used to demonstrate the inhibition of CYP27B1 promoter–dependent luciferase expression by FGF-23 [19] and to demonstrate CaSR-mediated upregulation of 2 immediate early genes, Egr-1 and AP-1 [46]. To facilitate our analyses, HEK-CaSR cells were transfected with a CYP27B1 promoter-Photinus pyralis firefly luciferase reporter gene and a control, herpes simplex virus (HSV) thymidine kinase (TK) promoter-Renilla luciferase construct as described previously [47].

To our surprise, we found that the CaSR mediates a complex, biphasic Ca2+o concentration–dependent response. At submaximal Ca2+o concentrations (0.5-3.0mM), the CaSR mediated transcriptional upregulation of CYP27B1-firefly luciferase. However, at maximal Ca2+o concentrations (≥5.0mM), the CaSR mediated a posttranscriptional downregulation of luciferase protein levels. Although luciferase and 1αOHase are clearly distinct proteins, the results indicate that at high Ca2+o concentrations the CaSR mediates enhanced breakdown of selected proteins with potential significance beyond the model HEK-293 cell/luciferase system described here.

Materials and Methods

Cell Culture

HEK-293 cells, or HEK-293 cells that stably express wild-type human CaSR (HEK-CaSR) or a T888A CaSR mutant (HEK-CaSRT888A) were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS; Bovogen Biologicals SFBS-AU), and 0.5% (v/v) penicillin-streptomycin in a humidified, 37 °C, 5% CO2 incubator. Cells were grown until 80% confluency, detached with 0.25% trypsin-EDTA (Gibco 11995), seeded into culture plates at ~30% confluency, and incubated for > 6 hours to adhere.

CYP27B1 Promoter-Luciferase Constructs

Plasmids containing the firefly luciferase reporter gene under the control of the human CYP27B1 promoter (CYP27B1-luciferase) and internal control Renilla luciferase reporter gene under the thymidine kinase (TK) promoter (pRL-TK; Promega) were developed previously [47]. CYP27B1-luciferase reporter constructs contain −1501 or −305 base pairs (bp) of the 5′ flanking region, and +42 bp of the 5′ untranslated region from the human CYP27B1 gene. These sequences had been cloned into the pGL3-Basic Vector, upstream of the firefly luciferase reporter gene (Promega), as described in (22).

Site-Directed Mutagenesis and PCR Amplification

Mutations of putative response elements were introduced into the CYP27B1-luciferase reporter constructs by polymerase chain reaction (PCR), using 25- to 30-base long forward and reverse primers. PCR was performed using the QuikChange II Site-Directed Mutagenesis Kit (Stratagene; La Jolla, CA) according to the manufacturer’s instructions, with DMSO included to reduce secondary structure formation. Where possible, nucleotide changes were selected based on those used in (22). A table of primers used in site-directed mutagenesis is provided in Supplemental Table 1 [48].

Truncations of the CYP2B1 promoter were generated by PCR amplification with MyTaq Polymerase (Bioline) using primers designed to anneal to the −1501 bp CYP27B1-luciferase construct at −100 and −200 bp, with an AscI restriction site included on the 5′ ends. The PCR product was digested with 5 U DpnI and 5 U AscI, and ligated into plasmid using 400 U T4 DNA ligase according to manufacturer’s instructions to generate the −102 and −200 bp CYP27B1 promoter-luciferase constructs. The PCR primers used to truncate the CYP27B1 promoter are provided in Supplemental Table 2 [48].

DNA samples were sequenced at the Australian Genome Research Facility (Brisbane, Australia) using primers described in Supplemental Table 3 [48]. The retrieved sequences were aligned against known sequences using Serial Cloner, version 2.6.

Transfection of HEK-CaSR Cells With Plasmid DNA

HEK-CaSR cells plated into 48-well plates were incubated in Ca2+ free DMEM (Gibco) supplemented with 0.5mM Ca2+o and 10% (v/v) FBS (Bovogen Biologicals SFBS-AU), and transiently transfected with luciferase constructs using X-tremeGENE HP DNA Transfection Reagent (Sigma Aldrich #06366236001) according to manufacturer’s instructions using a 4:1 ratio of transfection reagent to DNA and incubated for 48 hours.

Cell Incubations

Cells were incubated for 24 hours in Ca2+-free DMEM (Gibco 21068) supplemented with 0.2% bovine serum albumin (BSA; Sigma Aldrich A9576) and adjusted for Ca2+o using CaCl2. Cinacalcet and NPS-2143 (kindly provided by the Leach lab; The Monash Institute of Pharmaceutical Sciences) were used as positive and negative CaSR modulators respectively. To investigate the roles of signaling pathways, inhibitors were used to pretreat cells for 1 hour prior to 24-hour incubation. Following incubation the cells were washed once in chilled phosphate-buffered saline (PBS; 137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.8mM KH2PO4, pH 7.4) and lysates prepared as required for Dual-Luciferase Reporter (DLR) Assay System, quantitative real-time reverse transcriptase (RT)-PCR, or Western blotting.

Dual-Luciferase Reporter Assays

Cell lysates were prepared, and P. pyralis (firefly) and Renilla luciferase bioluminescence were generated using substrate solutions provided in the DLR Assay System (Promega E1910) according to the manufacturer’s instructions. Bioluminescence measurements were normalized for background (untransfected cell lysates) and expressed either as raw bioluminescence counts or as Relative Luciferase Activities, that is, as fold changes of firefly luciferase with respect to Renilla luciferase.

Quantitative Real-Time RT-PCR

RNA was isolated using TRI Reagent (Sigma Aldrich T9424), digested using DNase I (Sigma Aldrich AMPD1) to remove contaminating DNA, then reverse transcribed using Tetro cDNA Synthesis kit (Bioline BIO-65042) according to manufacturer’s instructions. Real-time PCR analyses were performed on diluted cDNA using the SensiFAST SYBR No-ROX Kit (Bioline BIO-98002) after identifying the linear range for cDNA dilutions and assessing melt temperature and amplicon sizes.

Relative expression levels were calculated by the 2-ΔΔCT method using the cycle threshold (CT) of the gene of interest and the housekeeping gene (RNA polymerase II) [49] obtained from Corbett Rotor-Gene 6000 Series Software 1.7.

Western Blotting—Antibodies

The following antibodies were used: Anti-firefly luciferase (rabbit polyclonal; Sigma #L0159; [50]); Anti-GAPDH (rabbit monoclonal; Cell Signaling Technology #2118; [51]); Anti-rabbit IgG-horseradish peroxidase [HRP] conjugated (goat polyclonal, Abcam #97051; [52]); Anti-CaSR phosphoT888 (rabbit polyclonal, custom-generated and affinity purified; [53]); Anti-CaSR total (mouse monoclonal, Thermo-Fisher #MA1-934; [54]); Anti-rabbit Ig-HRP conjugated (goat polyclonal, Agilent #P0448; [55]); Anti-mouse IgG-HRP conjugated (horse polyclonal, Cell Signaling Technology #7076; [56]).

Western Blotting—Procedures

Cells were lysed using a modified radioimmunoprecipitation assay (RIPA) buffer (25mM Tris-HCl, pH 7.6, 150mM NaCl, 1% NP40, 0.1% sodium dodecyl sulfate (SDS), 1% sodium deoxycholate, 1× Protease Inhibitor Cocktail [Cell Signaling Technology]) and triturated 30 times through a 21G needle. In some experiments the RIPA-like lysis buffer contained 12mM HEPES (pH 7.6), 300mM mannitol, 1mM EGTA, 1mM EDTA, 1% (v/v) Triton-X 100, 0.1% (w/v) SDS, 1mM NaF, 100μM sodium vanadate, 250μM sodium pyrophosphate, 1.25μM pepstatin, 4μM leupeptin, and 4.8μM PMSF. Protein samples were run through SDS-PAGE and transferred electrophoretically to 0.45-µm nitrocellulose membranes (Bio-Rad). Membranes were incubated in solutions containing antibodies against firefly luciferase or GAPDH according to manufacturers’ instructions, or against anti-phosphoCaSRT888 [57], and then HRP-conjugated secondary antibodies as listed above according to the species in which the primary antibodies were raised. The reaction catalyzed by HRP was initiated using Pierce ECL Western Blotting Substrate (Life Technologies Australia). Bands were visualized and densitometry analyses performed on a ChemiDoc MP Imaging System and Image Lab Software (Bio-Rad).

Statistical Analyses

The results are routinely expressed as means ± SEM. Statistical analyses were performed using 1-way analysis of variance (ANOVA) for Ca2+o concentration–response experiments, and 2-way ANOVA for studies involving CaSR modulators and inhibitors of signaling, followed by Sidak’s, Dunnett’s, or Tukey’s multiple comparisons test. P < 0.05 was used to assign statistical significance (GraphPad Prism 7.0).

Results

Effect of Elevated Ca2+o on Luciferase Activity

HEK-CaSR cells or control HEK-293 cells were transiently cotransfected with (i) firefly luciferase under the control of the CYP27B1 1501 bp promoter; and (ii) Renilla luciferase under the control of a constitutive HSV-TK promoter. The transfected cells were then exposed to various Ca2+o concentrations to determine the impact of CaSR activation on firefly luciferase, as a measure of CYP27B1 promoter function, and control Renilla luciferase activity.

In 3 initial experiments we incubated transfected HEK-CaSR cells with 3 different Ca2+o concentrations, 0.5mM, 3.0mM, and 5.0mM and analyzed both firefly and Renilla luciferase activities at 2, 4, 8, and 24 hours (Fig. 1). At 0.5mM Ca2+o, there was no change in the baseline level of either firefly or Renilla luciferase at any of the time points over the 24-hour period of the experiment. However, at 3.0mM Ca2+o, we observed a linear increase in firefly luciferase, but not Renilla luciferase, that was apparent after 4 hours and reached a level of around 2- to 4-fold of baseline after 24 hours (Fig. 1A). There was no significant change in Renilla luciferase activity from 2 to 24 hours at 3.0mM Ca2+o. Interestingly, at 5.0mM Ca2+o, we observed no significant changes in either firefly or Renilla luciferase at any of the time points studied over the course of the 24-hour period. Thus, we observed a striking biphasic Ca2+o concentration response for firefly luciferase, but not Renilla luciferase, which was maximal at 3.0mM Ca2+o (Fig. 1A) and dependent on the CYP27B1 promoter immediately upstream of the firefly luciferase gene. These effects were also apparent when they were expressed as Relative Luciferase Activity (firefly luciferase/Renilla luciferase; Fig. 1B) thereby using Renilla luciferase as a control for variations in transfection efficiency between experiments. Based on these effects we routinely expressed the data as Relative Luciferase Activity (RLA) and selected 24 hours as the standard incubation time.

Figure 1.

Figure 1.

Ca2+o concentration and time dependencies of firefly and Renilla luciferase activity in cotransfected HEK-CaSR cells. HEK-CaSR cells were transiently cotransfected with full-length (1501 bp) CYP27B1-firefly luciferase reporter gene and the TK-Renilla luciferase control gene, then incubated at various Ca2+o concentrations as shown for various times from 2 to 24 hours prior to analysis for both firefly and Renilla luciferases. In (A) the data from a single experiment performed in triplicate are expressed as separate firefly and Renilla luciferase activities. Similar results were obtained in 2 further experiments. In (B) the data were obtained in 3 experiments and are expressed as Relative Luciferase Activities.

We confirmed and extended these observations in subsequent experiments. Thus, HEK-CaSR cells elevated Ca2+o (3.0mM) stimulated firefly luciferase activity by 3- to 4- fold over 24 hours but had little or no effect on Renilla luciferase (Fig. 2A). However, as described above, HEK-CaSR cells exposed to 5.0mM or 8.0mM Ca2+o for 24 hours exhibited markedly reduced firefly luciferase activity when compared with the peak response at 3.0mM Ca2+o (P < 0.05), lying close to the baseline level observed at 0.5mM Ca2+o (Fig. 2A). No effect, however, was observed on Renilla luciferase.

Figure 2.

Figure 2.

Biphasic Ca2+o concentration–dependent control of relative luciferase activity in HEK-CaSR cells cotransfected with CYP27B1–firefly luciferase and control Renilla luciferase constructs. HEK-CaSR and HEK-293 cells were transiently cotransfected with full-length (1501 bp) CYP27B1-firefly luciferase reporter gene and the TK-Renilla luciferase control gene, then incubated for 24 hours at various Ca2+o concentrations prior to analysis for both firefly and Renilla luciferases. The results show the impacts of Ca2+o on the activities of: (A) firefly luciferase (open triangles) and Renilla luciferase (open circles) in HEK-CaSR cells; (B) Relative Luciferase Activity (firefly/Renilla) in HEK-CaSR cells; and (C) Relative Luciferase Activity in HEK-293 cells. The data were obtained in 4 independent experiments for panels A and B, and in 6 independent experiments in C. Luciferase activities were corrected for the background levels obtained in untransfected cells. Some errors lie entirely within the symbols.

When the results in Fig. 2A were expressed as RLA, elevated Ca2+o (3.0mM) induced a 2- to 3-fold increase over 24 hours when compared with control Ca2+o (0.5mM) in HEK-CaSR cells (Fig. 2B) but not in control HEK-293 cells that do not express the CaSR (Fig. 2C) and, consistent with the results in Fig. 2A, HEK-CaSR cells exposed to 5.0mM or 8.0mM Ca2+o for 24 hours exhibited markedly reduced RLA when compared with the peak response at 3.0mM Ca2+o (P < 0.05). These findings indicate that an increase in Ca2+o from 0.5mM to 3.0mM activated a CaSR-dependent stimulatory signaling pathway upstream of firefly luciferase expression but that a further increase in Ca2+o to 5.0mM or higher concentrations activated an inhibitory signaling pathway. Thus, the findings point to the existence of a biphasic response in the Ca2+o range from 0.5mM to 5.0mM, with a peak at approximately 3.0mM. Neither the stimulatory nor the inhibitory phases of the Ca2+o-dependent biphasic response in RLA could be detected at shorter time points ≤ 4 hours (3 independent experiments, not shown).

The CaSR Mediates Biphasic Control of Luciferase Activity

Transfected HEK-CaSR cells were next exposed to the CaSR positive allosteric modulator (PAM) cinacalcet, or the CaSR negative allosteric modulator (NAM) NPS-2143, to further investigate whether the CaSR mediates either 3.0mM Ca2+o-induced stimulation of firefly luciferase expression or 5.0mM Ca2+o-induced suppression.

Cinacalcet (1 µM) markedly enhanced RLA in cells exposed to control Ca2+o (0.5mM) for 24 hours and also suppressed RLA at 3.0mM (P < 0.01; Fig. 3A). However, there was no apparent change at 5.0mM (not shown). Thus, cinacalcet shifted the biphasic Ca2+o concentration–response relationship to the left, indicating that it had increased the Ca2+o sensitivity of both the stimulatory and inhibitory phases. The results are consistent with the conclusion that both phases of the response are CaSR dependent.

Figure 3.

Figure 3.

The CaSR mediates biphasic Ca2+o concentration–dependent control of CYP27B1 luciferase expression. Luciferase assays were performed on HEK-CaSR cells transiently cotransfected with the firefly luciferase reporter gene under the control of the CYP27B1 −1501 bp promoter, and the Renilla luciferase gene control under the HSV-TK promoter. Cells were incubated for 24 hours in 0.2% BSA supplemented DMEM in the presence of various Ca2+o, in the absence or presence of (A) cinacalcet (1µM) or (B) NPS-2143 (1µM). Firefly luciferase activities were corrected for background and expressed relative to Renilla luciferase activities. * P < 0.05; ** P < 0.01; *** P < 0.001 compared with 0.5mM Ca2+o; † P < 0.05; †† P < 0.01 compared with absence of modulator. Control data are shown at the left in both panels. The data were obtained in 4 and 7 independent experiments performed in triplicate for Figures A and B, respectively. (C) HEK-CaSR cells were incubated as described for (A) and (B) and Western blotting was performed for firefly luciferase protein. A representative Western blot is shown from 3 independent experiments. Abbreviation: U, untransfected HEK-CaSR control cells.

The CaSR negative modulator NPS-2143 (1 µM), on the other hand, appeared to right-shift the Ca2+o concentration–response curve. Thus, RLA was unchanged at the control Ca2+o of 0.5mM but significantly suppressed at Ca2+o 3.0mM (P < 0.01; Fig. 3B) and further increases in Ca2+o to 5.0mM or 7.0mM stimulated, rather than inhibited, RLA by around 3-fold, compared with the 0.5mM Ca2+o control (P < 0.001 compared with 0.5mM Ca2+o).

Similar results were obtained for firefly luciferase protein expression by Western blotting, in which band intensities increased 2.9 ± 0.4-fold at 3.0mM Ca2+o when compared with 0.5mM Ca2+o, then decreased at 5.0mM Ca2+o to levels comparable to control (Fig. 3C). Furthermore, the CaSR PAM cinacalcet shifted the biphasic response to the left, and the CaSR NAM NPS-2143 shifted it to the right. Densitometry analyses of the protein levels for the GAPDH control demonstrated that there were no significant differences between any of the treatments (not shown). These results indicate that the biphasic Ca2+o concentration–dependent changes in RLA arose from CaSR-mediated biphasic Ca2+o concentration–dependent changes in firefly luciferase protein levels.

Elevated Ca2+o Increases Luciferase mRNA Expression

We next performed quantitative RT-PCR for luciferase mRNA to investigate whether either 3.0mM Ca2+o-dependent stimulation or 5.0mM Ca2+o-dependent suppression of firefly luciferase activity was dependent on changes in firefly luciferase mRNA levels, that is, whether the changes in firefly luciferase activity were dependent on changes in the activation of the CYP27B1 promoter. As for luciferase we observed time-dependent increases in mRNA levels from 2 to 24 hours and selected 24 hours as a convenient time to undertake quantitations and comparisons. Thus, we observed increased (3.1 ± 0.5-fold) firefly luciferase mRNA levels in response to an increase in Ca2+o from 0.5mM to 3.0mM (P < 0.01; Fig. 4A), which resembled the observed increase in firefly luciferase enzyme activity (Figs. 1 and 2). The results are consistent with the conclusion that in HEK-CaSR cells exposed to 3.0mM Ca2+o, increases in firefly luciferase activity arose from enhanced transcription via the CYP27B1 promoter. Interestingly, unlike the observation for firefly luciferase activity, there was no significant difference in the level of firefly luciferase mRNA between that observed at 3.0mM Ca2+o and that observed at 5.0mM Ca2+o, which exhibited a 2.7 ± 0.6-fold elevation when compared with the 0.5mM Ca2+o control. The results indicate that the inhibition of firefly luciferase activity observed at 5.0mM Ca2+o when compared with 3.0mM Ca2+o did not arise from Ca2+o-dependent inhibition of transcription or loss of mRNA stability.

Figure 4.

Figure 4.

Ca2+o stimulated firefly luciferase and 1αOHase mRNA expression in transfected HEK-CaSR cells. Quantitative RT-PCR for (A) firefly luciferase expression was performed on HEK-CaSR cells transiently cotransfected with the firefly luciferase reporter gene under the CYP27B1 −1501 bp promoter, and the Renilla luciferase gene control under the HSV-TK promoter. Cells were incubated for 24 hours in 0.2% BSA supplemented DMEM at 0.5mM, 3.0mM, or 5.0mM Ca2+o. (B) 1αOHase expression was also quantified in untransfected HEK-CaSR cells and (C) HEK-293 cells, as described, for 0.5mM, 3.0mM, 5.0mM, or 7.0mM Ca2+o. mRNA expression levels were expressed as fold change with respect to the 0.5mM Ca2+o control, relative to RNA polymerase II using the 2−ΔΔCT method. * P < 0.05; ** P < 0.01; *** P < 0.001 compared with 0.5mM Ca2+o-treated cells using 1-way ANOVA with Dunnett’s post-test. The data in (A) were obtained in 5 independent experiments, (B) were obtained in 4 independent experiments, and (C) were obtained in 3 independent experiments, performed in duplicate.

Ca2+o-Dependent Increase of 1αOHase mRNA is CaSR-Mediated

We next investigated whether it was possible to detect endogenous 1αOHase mRNA and protein in HEK-CaSR and HEK-293 cells and, if so, whether the levels of either mRNA or protein might be modulated by Ca2+o. The 1αOHase mRNA levels exhibited an apparent 2- to 3-fold increase at 3.0mM Ca2+o and a 4- to 6-fold increase at 5.0mM Ca2+o at 24 hours. We were unable to detect, however, any Ca2+o-dependent changes in 1αOHase protein, which was at the limit of sensitivity of the Western blot assay.

We selected 24 hours for subsequent experiments on the Ca2+o concentration dependence of 1αOHase mRNA expression over an extended Ca2+o range of 0.5mM to 7.0mM. Increasing Ca2+o from 0.5mM to 3.0mM, 5.0mM, or 7.0mM increased 1αOHase mRNA levels in HEK-CaSR cells, with a maximal 3.4 ± 0.4-fold stimulation observed at 5.0mM Ca2+o (P < 0.001; Fig. 4B) and no significant difference in 1αOHase mRNA expression was observed as Ca2+o was increased between 5.0 mM and 7.0mM Ca2+o. Thus, we did not observe biphasic Ca2+o concentration–dependent control of 1αOHase mRNA expression in HEK-CaSR cells.

Ca2+o-stimulated increases in 1αOHase mRNA levels observed in HEK-CaSR cells were absent in control HEK-293 cells up to a Ca2+o of 7.0mM (Fig. 4C). Thus, the CaSR mediated Ca2+o-dependent increases in 1αOHase mRNA expression from 0.5mM to 7.0mM Ca2+o.

Effect of PKC Inhibitor on CaSR-Mediated Control of Luciferase Activity

Because we had demonstrated that the CaSR mediates (i) both the stimulatory and inhibitory control of RLA downstream of the CYP27B1 promoter as well as (ii) stimulatory control of 1αOHase mRNA levels in HEK-CaSR cells, we investigated the impacts on CYP27B1 promoter–dependent luciferase protein levels of selective inhibitors of key signaling pathways downstream of the CaSR, focusing first on PKC. Several PKC isoforms, including α and ε, are activated in response to the Ca2+o-stimulated CaSR [58, 59] and PKC is activated by either phosphoinositide-phospholipase C (PI-PLC)-dependent and/or -independent mechanisms downstream of G-protein coupled receptors (review: [60]). To investigate the role of PKC, HEK-CaSR cells were preincubated for 1 hour in the absence or presence of the potent PKC inhibitor GF109203X, a known inhibitor of PKC α, β 1, β 2, and γ [61] and the cells were then incubated for a further 24 hours in the continuing presence of GF109203X at 0.5mM, 3.0mM, or 5.0mM Ca2+o. GF109203X (0.5µM and 1µM) had no effect on basal RLA at 0.5mM Ca2+o or on 3.0mM Ca2+o-induced stimulation of RLA. Surprisingly, however, GF109203X (1μM) reversed the inhibitory effect observed at 5.0mM Ca2+o (Fig. 5A).

Figure 5.

Figure 5.

High Ca2+o-induced inhibition of CYP27B1-firefly luciferase: requirement for protein kinase C phosphorylation of CaSR C-terminus. (A) Effect of PKC inhibitor, GF109203X, on Ca2+o-dependent CYP27B1-firefly luciferase. Luciferase assays were performed on HEK-CaSR cells transiently cotransfected with the firefly luciferase reporter gene under the CYP27B1 −1501 bp promoter, and the Renilla luciferase gene control under the HSV-TK promoter. Cells were preincubated for 1 hour in 0.2% BSA supplemented DMEM at 0.5mM Ca2+o in the presence of vehicle (0.1% DMSO), GF109203X (GFX; 0.5μM or 1.0μM). The Ca2+o concentration was then either maintained at 0.5mM or increased to 3.0mM or 5.0mM for 24 hours. Firefly luciferase activities were corrected for background and expressed relative to Renilla luciferase activities. * P < 0.01; ** P < 0.001 compared with 0.5mM Ca2+o; † P < 0.05 compared with vehicle (0.1% DMSO). The data were obtained in 6 independent experiments performed in triplicate. (B) Effect of disabling CaSR T888 phosphorylation. Luciferase assays were performed on HEK-CaSR and HEK-CaSRT888A cells. Cells were transiently cotransfected with the firefly luciferase reporter gene under the CYP27B1 −1501 bp promoter, and the Renilla luciferase gene control under the HSV-TK promoter. Cells were incubated in 0.2% BSA supplemented DMEM in the presence of various Ca2+o in the absence or presence of cinacalcet for 24 hours. Firefly luciferase activities were corrected for background and expressed relative to Renilla luciferase activities. * P < 0.05; ** P < 0.001 compared with 0.5mM Ca2+o; † P < 0.001 compared with absence of cinacalcet; ‡ P < 0.05; ‡‡ P < 0.01; ‡‡‡ P < 0.001 compared with wild-type CaSR. The data were obtained in 6 independent experiments performed in triplicate.

Role of CaSR T888 Phosphorylation

Having identified a role for PKC in CaSR-mediated inhibitory control of CYP27B1-dependent luciferase expression, we investigated whether the key PKC phosphorylation site at CaSR residue T888 might be required for the effect using HEK-293 cells that stably expressed the CaSR mutant T888A (HEK-CaSRT888A), which disables the phosphorylation site [57, 62]. In pilot experiments, we observed an apparent loss of the inhibitory phase of the Ca2+o concentration–dependent relationship in HEK-CaSRT888A cells. For this reason, we performed the experiments over an extended Ca2+o range (0.5mM to 12mM).

HEK-CaSRT888A cells exhibited Ca2+o-stimulated firefly luciferase expression at 3.0mM that was comparable to that observed in HEK-CaSR cells, which, as noted above, express the wild-type CaSR (Fig. 5B). Furthermore, the CaSR PAM cinacalcet (1 µM) enhanced RLA at 0.5mM Ca2+o in HEK-CaSRT888A cells (P < 0.05; Fig. 5B).

However, unlike HEK-CaSR cells, 5.0mM to 12mM Ca2+o did not suppress RLA in HEK-CaSRT888A cells. Furthermore, cinacalcet failed to enhance the inhibitory effect of 5.0mM Ca2+o on RLA in HEK-CaSRT888A cells (Fig. 5B). The results indicate that CaSR-T888A supported the stimulatory phase of the Ca2+o-dependent relationship but was unable to support the inhibitory phase at higher Ca2+o concentrations (from 5.0mM to 12mM). They indicate further that PKC acting via T888 phosphorylation on the CaSR itself mediates the inhibitory effect of high Ca2+o on CYP27B1-dependent firefly luciferase expression.

Chronically Elevated Ca2+o Promotes CaSR T888 Phosphorylation

The effects of various Ca2+o concentrations on wild-type CaSR T888 phosphorylation were assessed using an epitope-specific antibody [57] over the extended incubation period used in the present study. In response to an increase in Ca2+o from 0.5mM to 3.0mM or 5.0mM over 24 hours, we observed a significant increase in T888 phosphorylation of the high mannose 140 kDa form but not the 160 kDa complex carbohydrate form and there was no significant difference in the phosphorylation state of T888 in lysates prepared from cells exposed to either 3.0mM or 5.0mM Ca2+o (Fig. 6A and 6B). These results demonstrate that elevated Ca2+o stimulates CaSR-mediated PKC-dependent T888 phosphorylation of the predominantly intracellular 140 kDa form and the results above with the PKC inhibitor GF109203X indicate that T888 phosphorylation is required for the inhibitory effect of high Ca2+o on CYP27B1-dependent firefly luciferase protein expression and enzyme activity. Surprisingly, however, we did not observe enhanced T888 phosphorylation at a Ca2+o concentration of 5.0mM when compared with Ca2+o 3.0mM, suggesting that high Ca2+o lowers firefly luciferase expression via an additional molecular step.

Figure 6.

Figure 6.

Impact of Ca 2+ o concentration on phosphorylation of CaSR residue T888. (A) Detection and quantitation of CaSR T888 phosphorylation, and total CaSR in HEK-CaSR cells that were incubated in 0.2% BSA supplemented DMEM at 0.5, 3.0, or 5.0mM Ca2+o for 24 hours, followed by Western blotting. Over the extended period of the experiment, we did not observe high Ca2+o-induced dephosphorylation of CaSR-T888. Representative Western blot from 6 independent experiments. (B) Quantitation of Western blot intensity data. In response to either 3.0mM or 5.0mM Ca2+o a stable increase in pCaSRT888 was observed for the 140 kDa (high mannose) form but not the 160 kDa (complex glycosylated) form.

Effect of ERK1/2 Inhibitor Alone and in Combination With the PKC Inhibitor on CaSR-Mediated Control of Luciferase Activity

The roles of mitogen-activated protein kinase kinase (MEK) and ERK1/2 in CaSR-mediated control of luciferase activity were assessed using PD184352 (10µM), a more potent and selective inhibitor of MEK than the previously used compound PD98059 [63, 64]. PD184352 appeared to have a marginal inhibitory effect on 3.0mM Ca2+o-stimulated RLA. In addition, PD184352, like the PKC inhibitor GF109203X, attenuated the inhibitory response at Ca2+o levels ≥ 5.0mM (Fig. 7A).

Figure 7.

Figure 7.

Effect of ERK inhibition and combined PKC/ERK inhibition on biphasic Ca2+o concentration–dependent control of CYP27B1-firefly luciferase. (A) Effect of MEK inhibitor, PD184352, on Ca2+o-dependent CYP27B1 −1501 bp promoter–controlled firefly luciferase expression in transfected HEK-CaSR cells. Luciferase assays were performed on HEK-CaSR cells transiently cotransfected with the firefly luciferase reporter gene (CYP27B1 −1501 bp promoter), and the Renilla luciferase gene. Cells were preincubated 1 hour in 0.2% BSA supplemented DMEM at 0.5mM Ca2+o in the absence or presence of PD184352 (10μM). The Ca2+o concentration was then either maintained at 0.5mM or increased up to various concentrations (from 3.0mM to 9.0mM) for 24 hours. Firefly luciferase activities were corrected for background and expressed relative to Renilla luciferase activities. * P < 0.01; ** P < 0.001 compared with 0.5mM Ca2+o. The data were obtained in 5 independent experiments, performed in triplicate. (B) Effects of PKC and MEK inhibitors alone and in combination on Ca2+o-dependent CYP27B1 promoter–dependent luciferase activity. Luciferase assays were performed on HEK-CaSR cells transiently cotransfected with the firefly luciferase reporter gene (CYP27B1 −1501 bp promoter), and the Renilla luciferase gene. Cells were preincubated 1 hour in 0.2% BSA supplemented DMEM at 0.5mM Ca2+o in the presence of vehicle (0.2% DMSO), or GF109203X (1µM) or PD184352 (10μM), or both these compounds. The Ca2+o concentration was then either maintained at 0.5mM or increased to 3.0mM or 5.0mM for 24 hours. Firefly luciferase activities were corrected for background and expressed relative to Renilla luciferase activities. * P < 0.01; ** P < 0.001 compared with 0.5mM Ca2+o; † P < 0.01; †† P < 0.001 compared with vehicle (0.2% DMSO). The data were obtained in 4 independent experiments performed in triplicate.

We then combined GF109203X (1µM) and PD184352 (10µM) to inhibit both PKC and MEK. Interestingly, this combination abrogated Ca2+o-dependent stimulation at both 3.0mM and 5.0mM Ca2+oFig. 7B), demonstrating that Ca2+o-dependent stimulation can be supported by either CaSR-mediated stimulation of ERK1/2 alone or PKC alone but cannot be supported by the CaSR if both pathways are blocked.

Role of Response Elements in the CYP27B1 Promoter

Finally, we investigated the role of the CYP27B1 promoter in luciferase expression, concentrating on the stimulatory effect at 3.0mM Ca2+o. To investigate the possible roles of response elements within the −1501 bp CYP27B1 promoter in CaSR-mediated increases in RLA and 1αOHase mRNA levels, the following truncated promoters, −305 bp, −200 bp, and −102 bp were studied (Table 1). The −305 bp promoter segment contains a number of putative response elements, including AP-1, NFkB, PU Box, CAAT Box(d), AP-2, CRE(p), Sp1(d), EBS(p), CCAAT, and Sp1(p) (Fig. 8A).

Table 1.

Effect of truncating the CYP27B1 −1501 bp promoter to −305 bp, −200 bp, or −102 bp on Ca2+o-stimulated firefly luciferase expression in transfected HEK-CaSR cells

Promoter construct Relative luciferase activity (RLA) RLA (fold change) n
0.5mM Ca2+o 3.0mM Ca2+o RLA (3mM Ca2+)/RLA (0.5mM Ca2+)
−1501 bp 8.2 ± 0.6 21.2 ± 1.8 2.6 ± 0.3 10
−305 bp 6.4 ± 0.7 15.6 ± 1.8 2.4 ± 0.4 10
−200 bp 19.3 ± 3.6* 34.5 ± 5.4** 1.8 ± 0.4 5
−102 bp 5.3 ± 1.0 10.4 ± 2.1** 1.9 ± 0.5 10

Luciferase assays were performed on HEK-CaSR cells transiently cotransfected with the firefly luciferase gene under the −1501 bp, −305 bp, −200 bp, or −102 bp CYP27B1 promoter, and the control Renilla luciferase gene under an HSV-TK promoter. Cells were incubated for 24 hours in 0.2% BSA supplemented DMEM at 0.5mM and 3.0mM Ca2+o. Firefly luciferase activities were corrected for background and expressed relative to Renilla luciferase activities. * P < 0.01; ** P < 0.001 compared with −1501 bp.

Abbreviations: bp, base pair; RLA, Relative Luciferase Activity.

Figure 8.

Figure 8.

Impacts of selected mutations of response elements in the −102 bp CYP27B1 promoter on Ca2+o-dependent stimulation of CYP27B1-dependent firefly luciferase expression in transfected HEK-CaSR cells. (A) Schematic representation of the −305 bp promoter and putative response elements. Transcription factor binding sites and locations are shown as described in (21, 22, 86). Abbreviations: AP-1, activator protein 1 binding site; AP-2, activator protein 2 binding site; CRE, cAMP response element; EBS, Ets-binding site; NFκB, nuclear factor kappa light-chain enhancer binding site; PU-box, purine rich enhancer sequence; and Sp1, specificity protein 1 binding sites. (B) Luciferase assays were performed on HEK-CaSR cells transiently cotransfected with the firefly luciferase reporter gene under the −305 bp wild-type, −102 bp wild-type, −102 bp CCAAT mutated, or –102 bp Sp1(p) mutated CYP27B1 promoter, and the Renilla luciferase control gene under the HSV-TK promoter. Cells were incubated for 24 hours in 0.2% BSA supplemented DMEM at 0.5mM and 3.0mM Ca2+o. Firefly luciferase activities were corrected for background and expressed relative to Renilla luciferase activities. * P < 0.001 compared with 0.5mM Ca2+o; † P < 0.001 compared with −305 bp promoter. The data were obtained in 6 independent experiments performed in triplicate.

Basal CYP27B1 promoter–dependent luciferase activity, observed at 0.5mM Ca2+o, was unchanged following truncation to either −305 bp or −102 bp, but was significantly increased by 2- to 3-fold in lysates prepared from cells transfected with the -200 bp promoter (P < 0.01; Table 1). Upon exposure to 3.0mM Ca2+o, and irrespective of the basal level of promoter activity, we observed similar 2- to 2.5-fold increases in RLA in all cases, even in the −102 bp promoter (P < 0.001). These results demonstrate that Ca2+o-dependent increases in mRNA levels arose from response elements contained within the −102 bp basal promoter.

We thus focused on mutations of recognized response elements in the −102 bp promoter segment (CCAAT and Sp1(p)) in both the −102 bp and −305 bp promoter constructs. In the case of the CCAAT mutant but not the Sp1(p) mutant, we observed a striking loss of transcription and no Ca2+o-dependent stimulation. This finding indicates that CCAAT is absolutely required for transcription from the CYP27B1 promoter as described previously [22, 65] and suggests that it is also required for the response to high Ca2+o (Fig. 8B). If CCAAT is responsible for Ca2+o-dependent stimulation, as well as basal promoter activity, the fact that it has been reported previously to be activated by both PKC and ERK1/2 would appear to be important [65]. Mutations of none of the other response elements tested, including Sp1(p), selectively disabled Ca2+o sensitivity (Supplemental Fig. 1; [48]).

Discussion

Previously, extracellular Ca2+ has been reported to control 1-alpha hydroxylase activity and thus the rate of 1,25-dihydroxyvitamin D synthesis both indirectly via, for example, impacts on PTH synthesis and secretion, and also directly in various tissue sites including the proximal tubule [27, 28], parathyroid [66], and osteoblasts [33]. However, the mechanisms by which Ca2+o modulates 1-alpha hydroxylase activity in these different tissue sites and acts to promote activity in some sites, such as parathyroid [66] and osteoblasts [33], but inhibits it in others, such as proximal tubule [27, 28], has not been determined. In considering how to investigate the molecular basis of these effects we noted that the CaSR, a key Ca2+o sensor with the ability to activate multiple signaling pathways downstream of the G proteins Gq/11, Gi/o, Gs, and G12/13 [67], is expressed and functional in all these tissue sites (review: [30]).

Thus, in the present study we decided to test whether the CaSR is able to mediate Ca2+o-dependent control of CYP27B1 (1-alpha hydroxylase) expression using a well-defined model cell system, HEK-CaSR cells that were transfected with plasmid DNA encoding the CYP27B1 promoter upstream of firefly luciferase. In particular, we quantified CYP27B1-dependent changes in firefly luciferase activity in response to various concentrations of Ca2+o in the absence or presence of positive or negative modulators of the CaSR. HEK-CaSR cells, HEK-293 cells that stably express the CaSR, are a widely recognized model for studies of CaSR-mediated cell signaling responses [68-74], in which Ca2+o concentration–response relationships, such as those for Ca2+i mobilization [68] and PI-PLC [69, 70] are submaximal in the range 0.5mM to 3.0mM and maximal in the range 5.0mM to 8.0mM. In HEK-CaSR cells we demonstrated that a submaximal increase in Ca2+o to 3.0mM stimulated firefly luciferase activity 2- to 3-fold associated with increased levels of firefly luciferase mRNA and protein. Surprisingly, however, at a near-maximal concentration of Ca2+o (5.0mM) with respect to PI-PLC and Ca2+i mobilization, and at higher Ca2+o concentrations, we observed markedly reduced levels of firefly luciferase activity (Fig. 1A and 2A) and protein (Fig. 3C), but not mRNA (Fig. 4A), which was elevated to the same level observed at 3.0mM. Thus, the positive effect on luciferase activity that was observed as Ca2+o increased from 0.5mM to 3.0mM was dependent on CYP27B1-mediated transcription. However, the inhibitory mechanism that we observed as Ca2+o levels increased above 3.0mM occurred downstream of mRNA levels, either at the level of protein synthesis or via a posttranslational effect.

Neither phase of the Ca2+o-dependent response was observed in control HEK-293 cells transfected with the luciferase reporter genes (Fig. 2C). In addition, in luciferase-transfected HEK-CaSR cells, the Ca2+o-dependent biphasic response was: (i) shifted to the left by the CaSR PAM cinacalcet (1µM); and (ii) shifted to the right by the CaSR NAM NPS-2143 (1µM; Fig. 3A and 3B). Together these results demonstrate that the CaSR mediates both phases of the response, that is, both the positive transcriptional mechanism and the negative posttranscriptional mechanism. Increasing Ca2+o concentrations also increased endogenous 1αOHase mRNA levels in HEK-CaSR cells, and as in the case of luciferase mRNA under the CYP27B1 promoter, there was no evidence of suppression of 1αOHase mRNA levels at higher Ca2+o concentrations. Thus, at submaximal concentrations, the Ca2+o-stimulated-CaSR mediated activation of the CYP27B1 promoter and consequent transcriptional upregulation. This is in clear distinction to the effect of FGF23, which suppressed CYP27B1-dependent 1αOHase in alpha-klotho-transfected HEK-293 cells [19], consistent with its effect in the kidney (review: [75]).

To determine the mechanism that underlies Ca2+o-stimulated activation of firefly luciferase mRNA expression, we performed various truncations and point mutations of the CYP27B1 promoter. Ca2+o concentration–dependent stimulation of luciferase activity was maintained following truncation of the CYP27B1 promoter from −1501 bp to −305 bp from the transcriptional start site, and indeed to −200 bp and −102 bp. However, we observed significant changes in baseline luciferase activity with these truncations (enhanced with the truncation to −200 bp and reduced with the truncation to −102 bp). These findings demonstrate that Ca2+o sensitivity is closely linked to the transcriptional start site (Supplemental Fig. 1; Panel J; [48]). The −102 bp segment of the promoter contains 2 well-defined response elements, CCAAT (−74 bp to −68 bp) and Sp1(p) (−53 bp to −48 bp) ([22]; Fig. 8A). Of these, the CCAAT box (ATTGGCT) is critical for CYP27B1 promoter function and responds to the transcription factor C/EBPβ (review: [65]), which is activated by Ca2+i, PKC, and ERK1/2 [76] (review: [65]). Mutation of the CCAAT box in the present study nearly abolished promoter function, as revealed by luciferase activity consistent with previous reports [22] and no longer supported Ca2+o-stimulated luciferase activity (Fig. 8B; Supplemental Fig. 1; [48]). Previously CCAAT box mutants were reported to abolish PTH-induced upregulation of CYP27B1 transcription although the proposed signaling mechanism required PKA [22]. In our studies mutation of the Sp1(p) site, on the other hand, suppressed total luciferase activity by around 50% without disturbing Ca2+o sensitivity. Thus, the results suggest that Ca2+o sensitivity is closely linked to the transcriptional start site of the CYP27B1 promoter and depends, at least in part, on the key CCAAT box response element at −74 bp to −68 bp downstream of the transcription factor C/EBPβ, which is activated by the 2 key cell signaling regulators we identified, PKC and ERK1/2.

In the present study, the importance of PKC for CaSR-mediated control of CYP27B1-dependent firefly luciferase was demonstrated by the impact of the potent PKC inhibitor GF109203X, which converted the biphasic Ca2+o concentration–dependent response to a monophasic increase (Fig. 5A). As PKCα phosphorylates CaSR residue T888 in response to elevated Ca2+o and thereby modulates CaSR-dependent signaling [77], we hypothesized and demonstrated that T888 phosphorylation is required for high Ca2+o-dependent inhibition of CYP27B1-dependent firefly luciferase. We therefore tested the effect of various Ca2+o concentrations on luciferase activity in HEK-293 cells that stably expressed the nonphosphorylatable CaSR mutant T888A (HEK-CaSRT888A cells). Elevated Ca2+o (0.5mM to 3.0mM) stimulated luciferase activity in HEK-CaSRT888A cells but no secondary Ca2+o-mediated suppression of luciferase activity was observed at Ca2+o levels ≥ 5.0mM, even up to 12mM (Fig. 5B). Taken together, the results indicate that Ca2+o-dependent suppression of luciferase activity in HEK-CaSR cells is mediated by PKC-dependent phosphorylation of CaSR residue T888.

Over short periods (up to 30 minutes) as Ca2+o increases and the CaSR is activated in HEK-CaSR cells, CaSRT888 is subjected first to phosphorylation and then to dephosphorylation as revealed by a CaSRT888 phospho-specific antibody [57, 72]. We wondered whether a similar pattern of behavior might occur over the longer periods (2-24 hours) of the experiments described here. Interestingly, although we were readily able to detect T888 phosphorylation in response to moderately elevated Ca2+o, 3.0mM, after 24 hours (Fig. 6), exposure of the cells to a higher Ca2+o concentration, 5.0mM, did not suppress T888 phosphorylation toward the baseline level as expected (Fig. 6). These results appear to demonstrate that in response to sustained exposure to high Ca2+o concentrations, and following T888 dephosphorylation, which supports large stepwise increases in Ca2+i [72], a further phase of phosphorylation occurs that is dependent, at least in part, on PKC activity. Calyculin A and endothall inhibit T888 dephosphorylation and lower Ca2+i toward baseline in HEK-CaSR cells acutely exposed to elevated Ca2+o [72]. However, in preliminary experiments neither of these inhibitors altered either phase of the biphasic Ca2+o concentration–dependent firefly luciferase response. Thus, the results demonstrate that T888 phosphorylation, rather than dephosphorylation, is responsible for high Ca2+o-induced suppression of CYP27B1-dependent luciferase protein levels downstream of elevated luciferase mRNA levels. The results also suggest that the T888-phosphorylated CaSR activates a biochemical pathway that suppresses protein synthesis and/or promotes protein breakdown.

We also considered whether another well-known mediator of CaSR signaling, the protein kinase ERK1/2 (review: [67]), might contribute to CaSR-mediated control of luciferase expression. ERK1/2 is activated via several mechanisms downstream of the CaSR in HEK-293 cells, including Gq/11 [58], Gi/o [78], transactivation of the EGF receptor [79], and β2 arrestin [80]. Interestingly, the activation of β2 arrestin is known to depend upon its binding to phosphorylated receptors (review: [81]). Thus, we tested the effect of PD184352 (10µM), a potent and selective inhibitor of MEK, which lies immediately upstream of ERK1/2 in signaling pathways. PD184352 induced a right-shift in the Ca2+o concentration–response relationship such that the maximum response was observed at 5.0mM Ca2+o rather than at 3.0mM Ca2+o. In addition, it reduced the level of secondary inhibition (with respect to baseline) from around 75% to 25% (Fig. 7B). These findings support the conclusion that ERK1/2 mediates the inhibitory mechanism, presumably downstream of CaSRT888 phosphorylation.

Surprisingly, when the PKC and MEK inhibitors were combined, Ca2+o-stimulated CYP27B1-luciferase was abolished (Fig. 7B). The results suggest that Ca2+o-stimulated CYP27B1-luciferase expression is supported: (i) in the presence of the PKC inhibitor GF109203X, by ERK1/2; and (ii) in the presence of the MEK inhibitor PD184352, by PKC. Thus, CYP27B1 promoter–dependent transcription appears to be activated in parallel by PKC and ERK1/2 converging on a common target sequence in the CCAAT box immediately upstream of the transcriptional start site.

The biphasic Ca2+o concentration–response relationship we observed would appear to have physiological significance from 2 perspectives. Firstly, the inhibitory effect of Ca2+o between submaximal and maximal concentrations would appear to be relevant to the control of renal proximal tubule 1αOHase activity, which is under tonic stimulation from PTH [20, 21]. If this is true, it provides further evidence for CaSR-mediated suppression of PTH-stimulated signaling in the proximal tubule. Previously, the CaSR was reported to disinhibit the PTH-induced inhibition of inorganic phosphate reabsorption [35]. Secondly, the stimulatory effect of Ca2+o at submaximal concentrations would appear to be relevant to the control of 1αOHase activity in the parathyroid [32] and other extrarenal tissues including bone-forming osteoblasts [33].

Mechanism Underlying Ca2+o-Dependent Inhibition of 1-Alpha Hydroxylase

In the present study, while we identified a transcriptional mechanism for the upregulation of CYP27B1 mRNA at submaximal Ca2+o, at maximal Ca2+o concentrations we observed reductions in luciferase activity and protein levels that were not accompanied by a reduction in mRNA levels. This finding is similar to that reported for 1αOHase in renal proximal tubular cells [28], raising the possibility that a common inhibitory mechanism that is Ca2+o-stimulated and CaSR-mediated may operate in both cases. If this is true, it is not transcriptional and it does not arise from impaired mRNA stability as firefly luciferase mRNA levels remained stably elevated over the 24-hour time course of these experiments at all Ca2+o concentrations tested above 3.0mM. For this reason, it seems likely that the inhibitory effect was exerted on translational or posttranslational activity, such as via enhanced protein breakdown.

While the effect might be exerted by a negative effect on translation, a mechanism of this type seems unlikely for two reasons. Firstly, although we identified a target sequence in the native 3′-UTR of P. pyralis luciferase, for a miRNA, miR-374, whose levels are modulated by the CaSR [82], in the plasmid construct we used, the native luciferase 3′UTR was replaced with a shortened 31-base sequence, which does not contain any recognized miR target sequences (mirdb.org). Secondly, although cell signaling pathways can control general rates of translation, such as via the regulation of mTOR and S6 kinase activity, we did not observe any Ca2+o-stimulated suppression of Renilla luciferase activity in experiments in which high Ca2+o robustly lowered firefly luciferase activity and protein levels (Figs. 1-3).

Thus, it seems more likely that the inhibitory effect is exerted via a signaling pathway linked to a posttranslational effect, such as protein breakdown. In our Western blot studies of Ca2+o-stimulated control of luciferase protein expression we did not observe lower molecular weight fragments that might have pointed to a proteolytic mechanism. On the other hand, Ca2+i-dependent and -independent signaling pathways have been identified that stimulate the intracellular activation and/or release of proteases. The cell-permeant inhibitor of the Ca2+i-dependent protease calpain, Calpain Inhibitor I, did not prevent high Ca2+o-induced suppression of luciferase activity in the present study. Another candidate is the mitochondrial serine protease Omi/HtrA, which localizes to the mitochondrial intermembrane space in close proximity to 1α-OHase. Omi/HtrA was previously shown to be activated and released via a PP2A-dependent signaling pathway [83]. The Ca2+o-stimulated CaSR activates PP2A in association with T888 phosphorylation [72] and may thus induce the activation and release of Omi/HtrA with the ability to cleave luciferase and perhaps other cellular protein targets. Consistent with this idea, firefly luciferase is highly sensitive to proteolytic degradation [84], and a specific serine protease-selective site has been identified [85]. 1αOHase is also highly sensitive to proteolytic degradation by proteases, including the serine proteases trypsin and chymotrypsin but not caspases (https://web.expasy.org/peptide_cutter/) and PP2A-stimulated activation and/or release of the serine protease Omi/HtrA might thereby provide a mechanism by which maximal Ca2+o stimulation of the CaSR suppresses 1αOHase activity. Based on our findings, the possibility that the CaSR mediates proteolytic degradation of 1αOHase requires further consideration.

Finally, it might be wondered what impacts activating and inactivating CaSR mutations linked to human autosomal dominant hypocalcemia and familial hypocalciuric hypercalcemia [30] respectively might have on 1αOHase activity. In fact, it seems plausible that the effects may be minor due to the compensatory effect of a reduced plasma calcium concentration in the context of activating mutations and an increased plasma calcium concentration in the context of inactivating mutations.

In conclusion, we have demonstrated CaSR-mediated biphasic Ca2+o concentration–dependent control of CYP27B1 promoter–dependent firefly luciferase activity in HEK-293 cells. At submaximal Ca2+o, the CaSR mediates Ca2+o-stimulated activation of the CYP27B1 promoter dependent on 2 parallel signaling pathways in which the CaSR links to PKC and ERK1/2 and converges on the CCAAT box immediately upstream of the transcriptional start site. At maximal Ca2+o, the CaSR mediates a posttranscriptional mechanism, most probably protein breakdown, dependent upon a mechanism that links the CaSR to phosphorylation of CaSR residue T888 via PKCα and to an ERK1/2-dependent pathway, presumably downstream of CaSRT888 phosphorylation. The results demonstrate the existence of complex Ca2+o-dependent control of CYP27B1 promoter–dependent firefly luciferase and are consistent with hypotheses that the CaSR mediates both positive control of 1αOHase activity in the parathyroid, skeleton, and other extrarenal tissues, along with negative control of 1αOHase activity in the renal proximal tubule.

Acknowledgments

A.D.C. and D.T.W. thank the National Health & Medical Research Council of Australia for the award of project grant APP1011922. The work was inspired by the scholarly example, collaborative spirit, energy, and friendly enthusiasm of our colleague, the late Professor Howard Morris of the University of South Australia. We also thank Professor Arthur Christopoulos and Dr Katie Leach, who generously provided cinacalcet and NPS-2143 for the studies.

Author Contributions: Dr. Alice Huang contributed to project design, performed the majority of experiments together with their analysis, and helped to draft, revise, and correct the manuscript. Dr. Binmahfouz performed the experiments on T888 phosphorylation of the calcium-sensing receptor and helped to revise and correct the manuscript. Dr. Dale Hancock contributed to the design, supervision, and analysis of experiments using quantitative PCR and helped to revise and correct the manuscript. Professor Paul Anderson developed the 2 primary CYP27B1 constructs (−1501 and −305), assisted with overall project design, and helped to revise and correct the manuscript. Professor Donald Ward supervised the experiments on T888 phosphorylation of the calcium-sensing receptor including performance and analysis and helped to revise and correct the manuscript. Professor Arthur Conigrave was responsible for overall project design, supervised the majority of experiments and their analysis, and drafted, revised, and corrected the manuscript.

Glossary

Abbreviations

1,25(OH)2D3

1α,25-dihydroxyvitamin D3, calcitriol

1αOHase

25-hydroxyvitamin D 1α-hydroxylase

ANOVA

analysis of variance

BSA

bovine serum albumin

Ca2+o

extracellular Ca2+

CaSR

calcium-sensing receptor

DMEM

Dulbecco’s Modified Eagle Medium

ERK

extracellular regulated protein kinase

FBS

fetal bovine serum

FGF23

fibroblast growth factor 23

HRP

horseradish peroxidase

HSV

herpes simplex virus

MEK

mitogen-activated protein kinase kinase

NAM

negative allosteric modulator

PAM

positive allosteric modulator

PI-PLC

phosphoinositide-phospholipase C

PKC

protein kinase C

PTH

parathyroid hormone

RLA

Relative Luciferase Activity

SDS

sodium dodecyl sulfate

SDS-PAGE

sodium dodecyl sulfate–polyacrylamide gel electrophoresis

TK

tyrosine kinase

Additional Information

Disclosures : All authors declare that they have no conflicts of interest.

Data Availability

Some or all data generated or analyzed during this study are included in this published article or in the data repositories listed in References.

References

  • 1. Brunette MG, Chan M, Ferriere C, Roberts KD. Site of 1,25(OH)2 vitamin D3 synthesis in the kidney. Nature. 1978;276(5685):287-289. [DOI] [PubMed] [Google Scholar]
  • 2. DeLuca HF. Vitamin D: Historical Overview. Vitam Horm. 2016;100:1-20. [DOI] [PubMed] [Google Scholar]
  • 3. Fleet JC. The role of vitamin D in the endocrinology controlling calcium homeostasis. Mol Cell Endocrinol. 2017;453:36-45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Goltzman D, Mannstadt M, Marcocci C. Physiology of the Calcium-Parathyroid Hormone-Vitamin D Axis. Front Horm Res. 2018;50:1-13. [DOI] [PubMed] [Google Scholar]
  • 5. Bouillon R, Bikle D. Vitamin D Metabolism Revised: Fall of Dogmas. J Bone Miner Res. 2019;34(11):1985-1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Fu GK, Lin D, Zhang MY, et al. Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol Endocrinol. 1997;11(13):1961-1970. [DOI] [PubMed] [Google Scholar]
  • 7. Fraser D, Kooh SW, Kind HP, Holick MF, Tanaka Y, DeLuca HF. Pathogenesis of hereditary vitamin-D-dependent rickets. An inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin D. N Engl J Med. 1973;289(16):817-822. [DOI] [PubMed] [Google Scholar]
  • 8. Goltzman D, Miao D, Panda DK, Hendy GN. Effects of calcium and of the Vitamin D system on skeletal and calcium homeostasis: lessons from genetic models. J Steroid Biochem Mol Biol. 2004;89-90(1-5):485-489. [DOI] [PubMed] [Google Scholar]
  • 9. Okazaki T, Igarashi T, Kronenberg HM. 5’-flanking region of the parathyroid hormone gene mediates negative regulation by 1,25-(OH)2 vitamin D3. J Biol Chem. 1988;263(5):2203-2208. [PubMed] [Google Scholar]
  • 10. Mackey SL, Heymont JL, Kronenberg HM, Demay MB. Vitamin D receptor binding to the negative human parathyroid hormone vitamin D response element does not require the retinoid x receptor. Mol Endocrinol. 1996;10(3):298-305. [DOI] [PubMed] [Google Scholar]
  • 11. Kawahara M, Iwasaki Y, Sakaguchi K, et al. Predominant role of 25OHD in the negative regulation of PTH expression: clinical relevance for hypovitaminosis D. Life Sci. 2008;82(13-14):677-683. [DOI] [PubMed] [Google Scholar]
  • 12. Panda DK, Miao D, Bolivar I, et al. Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem. 2004;279(16):16754-16766. [DOI] [PubMed] [Google Scholar]
  • 13. Naja RP, Dardenne O, Arabian A, St Arnaud R. Chondrocyte-specific modulation of Cyp27b1 expression supports a role for local synthesis of 1,25-dihydroxyvitamin D3 in growth plate development. Endocrinology. 2009;150(9):4024-4032. [DOI] [PubMed] [Google Scholar]
  • 14. Adams JS, Rafison B, Witzel S, et al. Regulation of the extrarenal CYP27B1-hydroxylase. J Steroid Biochem Mol Biol. 2014;144(Pt A):22-27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Murayama A, Takeyama K, Kitanaka S, et al. Positive and negative regulations of the renal 25-hydroxyvitamin D3 1alpha-hydroxylase gene by parathyroid hormone, calcitonin, and 1alpha,25(OH)2D3 in intact animals. Endocrinology. 1999;140(5):2224-2231. [DOI] [PubMed] [Google Scholar]
  • 16. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113(4):561-568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19(3):429-435. [DOI] [PubMed] [Google Scholar]
  • 18. Bajwa A, Forster MN, Maiti A, Woolbright BL, Beckman MJ. Specific regulation of CYP27B1 and VDR in proximal versus distal renal cells. Arch Biochem Biophys. 2008;477(1):33-42. [DOI] [PubMed] [Google Scholar]
  • 19. Chanakul A, Zhang MY, Louw A, et al. FGF-23 regulates CYP27B1 transcription in the kidney and in extra-renal tissues. Plos One. 2013;8(9):e72816. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Brenza HL, Kimmel-Jehan C, Jehan F, et al. Parathyroid hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter. Proc Natl Acad Sci U S A. 1998;95(4):1387-1391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Kong XF, Zhu XH, Pei YL, Jackson DM, Holick MF. Molecular cloning, characterization, and promoter analysis of the human 25-hydroxyvitamin D3-1alpha-hydroxylase gene. Proc Natl Acad Sci U S A. 1999;96(12):6988-6993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Gao XH, Dwivedi PP, Choe S, et al. Basal and parathyroid hormone induced expression of the human 25-hydroxyvitamin D 1alpha-hydroxylase gene promoter in kidney AOK-B50 cells: role of Sp1, Ets and CCAAT box protein binding sites. Int J Biochem Cell Biol. 2002;34(8):921-930. [DOI] [PubMed] [Google Scholar]
  • 23. Zierold C, Nehring JA, DeLuca HF. Nuclear receptor 4A2 and C/EBPbeta regulate the parathyroid hormone-mediated transcriptional regulation of the 25-hydroxyvitamin D3-1alpha-hydroxylase. Arch Biochem Biophys. 2007;460(2):233-239. [DOI] [PubMed] [Google Scholar]
  • 24. Zhong Y, Armbrecht HJ, Christakos S. Calcitonin, a regulator of the 25-hydroxyvitamin D3 1alpha-hydroxylase gene. J Biol Chem. 2009;284(17):11059-11069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Takeyama K, Kitanaka S, Sato T, Kobori M, Yanagisawa J, Kato S. 25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis. Science. 1997;277(5333):1827-1830. [DOI] [PubMed] [Google Scholar]
  • 26. Favus MJ, Langman CB. Evidence for calcium-dependent control of 1,25-dihydroxyvitamin D3 production by rat kidney proximal tubules. J Biol Chem. 1986;261(24):11224-11229. [PubMed] [Google Scholar]
  • 27. Weisinger JR, Favus MJ, Langman CB, Bushinsky DA. Regulation of 1,25-dihydroxyvitamin D3 by calcium in the parathyroidectomized, parathyroid hormone-replete rat. J Bone Miner Res. 1989;4(6):929-935. [DOI] [PubMed] [Google Scholar]
  • 28. Bland R, Walker EA, Hughes SV, Stewart PM, Hewison M. Constitutive expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in a transformed human proximal tubule cell line: evidence for direct regulation of vitamin D metabolism by calcium. Endocrinology. 1999;140(5):2027-2034. [DOI] [PubMed] [Google Scholar]
  • 29. Tanaka Y, Deluca HF. The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus. Arch Biochem Biophys. 1973;154(2):566-574. [DOI] [PubMed] [Google Scholar]
  • 30. Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev. 2001;81(1):239-297. [DOI] [PubMed] [Google Scholar]
  • 31. Centeno PP, Herberger A, Mun HC, et al. Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion. Nat Commun. 2019;10(1):4693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Ritter CS, Haughey BH, Armbrecht HJ, Brown AJ. Distribution and regulation of the 25-hydroxyvitamin D3 1α-hydroxylase in human parathyroid glands. J Steroid Biochem Mol Biol. 2012;130(1-2):73-80. [DOI] [PubMed] [Google Scholar]
  • 33. Meijden Kvd, Essen Hv, Bloemers F, Schulten E, Lips P, Bravenboer N. Regulation of CYP27B1 mRNA Expression in Primary Human Osteoblasts. Calcif Tissue Int. 2016;99:164-173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Graca JA, Schepelmann M, Brennan SC, et al. Comparative expression of the extracellular calcium-sensing receptor in the mouse, rat, and human kidney. Am J Physiol Renal Physiol. 2016;310(6):F518-F533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Ba J, Brown D, Friedman PA. Calcium-sensing receptor regulation of PTH-inhibitable proximal tubule phosphate transport. Am J Physiol Renal Physiol. 2003;285(6):F1233-F1243. [DOI] [PubMed] [Google Scholar]
  • 36. Chang W, Tu C, Chen TH, et al. Expression and signal transduction of calcium-sensing receptors in cartilage and bone. Endocrinology. 1999;140(12):5883-5893. [DOI] [PubMed] [Google Scholar]
  • 37. Santa Maria C, Cheng Z, Li A, et al. Interplay between CaSR and PTH1R signaling in skeletal development and osteoanabolism. Semin Cell Dev Biol. 2016;49:11-23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Rybchyn MS, Slater M, Conigrave AD, Mason RS. An Akt-dependent increase in canonical Wnt signaling and a decrease in sclerostin protein levels are involved in strontium ranelate-induced osteogenic effects in human osteoblasts. J Biol Chem. 2011;286(27):23771-23779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Rybchyn MS, Islam KS, Brennan-Speranza TC, et al. Homer1 mediates CaSR-dependent activation of mTOR complex 2 and initiates a novel pathway for AKT-dependent β-catenin stabilization in osteoblasts. J Biol Chem. 2019;294(44):16337-16350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Chang W, Tu C, Chen TH, Bikle D, Shoback D. The extracellular calcium-sensing receptor (CaSR) is a critical modulator of skeletal development. Sci Signal. 2008;1(35):ra1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Riccardi D, Valenti G. Localization and function of the renal calcium-sensing receptor. Nat Rev Nephrol. 2016;12(7):414-425. [DOI] [PubMed] [Google Scholar]
  • 42. Kifor O, Diaz R, Butters R, Kifor I, Brown EM. The calcium-sensing receptor is localized in caveolin-rich plasma membrane domains of bovine parathyroid cells. J Biol Chem. 1998;273(34):21708-21713. [DOI] [PubMed] [Google Scholar]
  • 43. Goltzman D, Hendy GN. The calcium-sensing receptor in bone–mechanistic and therapeutic insights. Nat Rev Endocrinol. 2015;11(5):298-307. [DOI] [PubMed] [Google Scholar]
  • 44. Mithal A, Kifor O, Kifor I, et al. The reduced responsiveness of cultured bovine parathyroid cells to extracellular Ca2+ is associated with marked reduction in the expression of extracellular Ca(2+)-sensing receptor messenger ribonucleic acid and protein. Endocrinology. 1995;136(7):3087-3092. [DOI] [PubMed] [Google Scholar]
  • 45. Kang H, Lim J, Noh K, et al. Effective reconstruction of functional organotypic kidney spheroid for in vitro nephrotoxicity studies. Sci Rep. 2019;9(1):17610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Thiel G, Lesch A, Keim A. Transcriptional response to calcium-sensing receptor stimulation. Endocrinology. 2012;153(10):4716-4728. [DOI] [PubMed] [Google Scholar]
  • 47. Turner AG, Dwivedi PP, May BK, Morris HA. Regulation of the CYP27B1 5’-flanking region by transforming growth factor-beta in ROS 17/2.8 osteoblast-like cells. J Steroid Biochem Mol Biol. 2007;103(3-5):322-325. [DOI] [PubMed] [Google Scholar]
  • 48. Huang A, Binmahfouz L, Hancock DP, Anderson PH, Ward DT, Conigrave AD.. Data from: Calcium-sensing receptors control CYP27B1-luciferase expression. Transcriptional and post-transcriptional mechanisms. University of Sydney SeS Repository. 2021. Deposited March 19, 2021. doi:10.25910/3ka2-1r16. https://hdl.handle.net/2123/24687. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-408. [DOI] [PubMed] [Google Scholar]
  • 50. Anti-firefly luciferase antibody (rabbit polyclonal; Sigma #L0159). Creative Diagnostics; RRID: AB_260379.
  • 51. Anti-GAPDH antibody (rabbit monoclonal; Cell Signaling Technology #2118). Creative Diagnostics; RRID: AB_561053.
  • 52. Anti-rabbit IgG-HRP conjugated antibody (goat polyclonal, Abcam #97051). Creative Diagnostics; RRID: AB_10679369.
  • 53. Anti-CaSR phosphoThr-888 antibody (rabbit polyclonal, affinity purified). RRID: AB_2890168.
  • 54. Anti-CaSR total antibody (mouse monoclonal, Thermo-Fisher #MA1-934). Creative Diagnostics; RRID: AB_325374.
  • 55. Anti-rabbit Ig-HRP conjugated antibody (goat polyclonal, Agilent #P0448). Creative Diagnostics; RRID: AB_2617138.
  • 56. Anti-mouse IgG-HRP conjugated antibody (horse polyclonal, Cell Signaling Technology #7076). Creative Diagnostics; RRID: AB_330924.
  • 57. Davies SL, Ozawa A, McCormick WD, Dvorak MM, Ward DT. Protein kinase C-mediated phosphorylation of the calcium-sensing receptor is stimulated by receptor activation and attenuated by calyculin-sensitive phosphatase activity. J Biol Chem. 2007;282(20):15048-15056. [DOI] [PubMed] [Google Scholar]
  • 58. Kifor O, MacLeod RJ, Diaz R, et al. Regulation of MAP kinase by calcium-sensing receptor in bovine parathyroid and CaR-transfected HEK293 cells. Am J Physiol Renal Physiol. 2001;280(2):F291-F302. [DOI] [PubMed] [Google Scholar]
  • 59. Sakwe AM, Larsson M, Rask L. Involvement of protein kinase C-alpha and -epsilon in extracellular Ca(2+) signalling mediated by the calcium sensing receptor. Exp Cell Res. 2004;297(2):560-573. [DOI] [PubMed] [Google Scholar]
  • 60. Rozengurt E. Mitogenic signaling pathways induced by G protein-coupled receptors. J Cell Physiol. 2007;213(3):589-602. [DOI] [PubMed] [Google Scholar]
  • 61. Toullec D, Pianetti P, Coste H, et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem. 1991;266(24):15771-15781. [PubMed] [Google Scholar]
  • 62. Young SH, Wu SV, Rozengurt E. Ca2+-stimulated Ca2+ oscillations produced by the Ca2+-sensing receptor require negative feedback by protein kinase C. J Biol Chem. 2002;277(49):46871-46876. [DOI] [PubMed] [Google Scholar]
  • 63. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000;351(Pt 1):95-105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007;408(3):297-315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65. Ramji DP, Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J. 2002;365(Pt 3):561-575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66. Ritter CS, Haughey BH, Armbrecht HJ, Brown AJ. Distribution and regulation of the 25-hydroxyvitamin D3 1α-hydroxylase in human parathyroid glands. J Steroid Biochem Mol Biol. 2012;130(1-2):73-80. [DOI] [PubMed] [Google Scholar]
  • 67. Conigrave AD, Ward DT. Calcium-sensing receptor (CaSR): pharmacological properties and signaling pathways. Best Pract Res Clin Endocrinol Metab. 2013;27(3):315-331. [DOI] [PubMed] [Google Scholar]
  • 68. Bai M, Quinn S, Trivedi S, et al. Expression and characterization of inactivating and activating mutations in the human Ca2+o-sensing receptor. J Biol Chem. 1996;271(32):19537-19545. [DOI] [PubMed] [Google Scholar]
  • 69. Kifor O, Diaz R, Butters R, Brown EM. The Ca2+-sensing receptor (CaR) activates phospholipases C, A2, and D in bovine parathyroid and CaR-transfected, human embryonic kidney (HEK293) cells. J Bone Miner Res. 1997;12(5):715-725. [DOI] [PubMed] [Google Scholar]
  • 70. Ray K, Fan GF, Goldsmith PK, Spiegel AM. The carboxyl terminus of the human calcium receptor. Requirements for cell-surface expression and signal transduction. J Biol Chem. 1997;272(50):31355-31361. [DOI] [PubMed] [Google Scholar]
  • 71. Breitwieser GE, Gama L. Calcium-sensing receptor activation induces intracellular calcium oscillations. Am J Physiol Cell Physiol. 2001;280(6):C1412-C1421. [DOI] [PubMed] [Google Scholar]
  • 72. McCormick WD, Atkinson-Dell R, Campion KL, Mun HC, Conigrave AD, Ward DT. Increased receptor stimulation elicits differential calcium-sensing receptor(T888) dephosphorylation. J Biol Chem. 2010;285(19):14170-14177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73. Nesbit MA, Hannan FM, Howles SA, et al. Mutations affecting G-protein subunit α11 in hypercalcemia and hypocalcemia. N Engl J Med. 2013;368(26):2476-2486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74. Brennan SC, Mun HC, Leach K, Kuchel PW, Christopoulos A, Conigrave AD. Receptor expression modulates calcium-sensing receptor mediated intracellular Ca2+ mobilization. Endocrinology. 2015;156(4):1330-1342. [DOI] [PubMed] [Google Scholar]
  • 75. Perwad F, Portale AA. Vitamin D metabolism in the kidney: regulation by phosphorus and fibroblast growth factor 23. Mol Cell Endocrinol. 2011;347(1-2):17-24. [DOI] [PubMed] [Google Scholar]
  • 76. Wegner M, Cao Z, Rosenfeld MG. Calcium-regulated phosphorylation within the leucine zipper of C/EBP beta. Science. 1992;256(5055):370-373. [DOI] [PubMed] [Google Scholar]
  • 77. Young SH, Rey O, Sinnett-Smith J, Rozengurt E. Intracellular Ca2+ oscillations generated via the Ca2+-sensing receptor are mediated by negative feedback by PKCα at Thr888. Am J Physiol Cell Physiol. 2014;306(3):C298-C306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78. Holstein DM, Berg KA, Leeb-Lundberg LM, Olson MS, Saunders C. Calcium-sensing receptor-mediated ERK1/2 activation requires Galphai2 coupling and dynamin-independent receptor internalization. J Biol Chem. 2004;279(11):10060-10069. [DOI] [PubMed] [Google Scholar]
  • 79. MacLeod RJ, Yano S, Chattopadhyay N, Brown EM. Extracellular calcium-sensing receptor transactivates the epidermal growth factor receptor by a triple-membrane-spanning signaling mechanism. Biochem Biophys Res Commun. 2004;320(2):455-460. [DOI] [PubMed] [Google Scholar]
  • 80. Gorvin C, Babinsky V, Malinauskas T, et al. A calcium-sensing receptor mutation causing hypocalcemia disrupts a transmembrane salt bridge to activate β-arrestin-biased signaling. Sci Signal. 2018;11(518):eaan3714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81. Luttrell LM, Lefkowitz RJ. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci. 2002;115(Pt 3):455-465. [DOI] [PubMed] [Google Scholar]
  • 82. Gong Y, Renigunta V, Himmerkus N, et al. Claudin-14 regulates renal Ca⁺⁺ transport in response to CaSR signalling via a novel microRNA pathway. Embo J. 2012;31(8):1999-2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83. Wang CY, Lin YS, Su WC, Chen CL, Lin CF. Glycogen synthase kinase-3 and Omi/HtrA2 induce annexin A2 cleavage followed by cell cycle inhibition and apoptosis. Mol Biol Cell. 2009;20(19):4153-4161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84. Thompson JF, Hayes LS, Lloyd DB. Modulation of firefly luciferase stability and impact on studies of gene regulation. Gene. 1991;103(2):171-177. [DOI] [PubMed] [Google Scholar]
  • 85. Thompson JF, Geoghegan KF, Lloyd DB, et al. Mutation of a protease-sensitive region in firefly luciferase alters light emission properties. J Biol Chem. 1997;272(30):18766-18771. [DOI] [PubMed] [Google Scholar]
  • 86. Dwivedi PP, Anderson PH, Omdahl JL, Grimes HL, Morris HA, May BK. Identification of growth factor independent-1 (GFI1) as a repressor of 25-hydroxyvitamin D 1-alpha hydroxylase (CYP27B1) gene expression in human prostate cancer cells. Endocr Relat Cancer. 2005;12(2):351-365. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Some or all data generated or analyzed during this study are included in this published article or in the data repositories listed in References.


Articles from Journal of the Endocrine Society are provided here courtesy of The Endocrine Society

RESOURCES